Extended indication Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and su
Therapeutic value No judgement
Total cost 53,100,000.00

Product

Active substance Pembrolizumab
Domain Oncology and Hematology
Main indication Stomach cancer
Extended indication Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line.
Proprietary name Keytruda
Manufacturer MSD
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Expected Registration October 2018
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

574 - 1,550

Market share is generally not included unless otherwise stated.

References NKR
Additional remarks In 2014/2015 waren er gemiddeld 1550 nieuwe patiënten met cardia of non-cardia maagadenocarcinoom. Ongeveer een derde van deze patiënten werd niet behandeld in de 1e lijn. Daarnaast werden 350 patiënten per jaar behandeld met palliatieve chemotherapie. Schatting voor percentage patiënten dat na progressie op 1e lijns systemische therapie start met 2e lijns systemische therapie is 37%.

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
References Medicijnkosten.nl
Additional remarks €3.355,96 per injectieflacon van 4 ml, 25 mg/ml.

Potential total cost per year

Total cost

53,100,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.